Milestones :: Perspectives :: Research

COVID Vaccines Development/Procurement/Distribution/Policy – Russia, China

Russia: Sputnik V – “the first registered COVID-19 vaccine” [to 2 Jan 2021]
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
RDIF to supply 2.6 million doses of Russian Sputnik V coronavirus vaccine to Bolivia
Press release, 30.12.2020
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and the Health Supply Centre (Central de Abastecimiento y Suministros de Salud, CEASS) of the Plurinational State of Bolivia announce the agreement to supply the country with 2.6 million doses of Sputnik V, the world’s first registered vaccine against coronavirus…
The agreement will make it possible for more than 20% of Bolivia’s population to access the vaccine. Supply of the vaccine will be facilitated by RDIF’s international partners in India, China, South Korea and other countries….

Belarus starts vaccination with Sputnik V
Press release, 29.12.2020
Belarus has become the first country after Russia to start vaccinating its population with Sputnik V
…First batch of the vaccine arrived in Belarus today.
Belarus was the first country to officially register Sputnik V after Russia. The registration certificate was granted on December 21, 2020. On October 1, Belarus was also the first foreign country to begin clinical trials of Sputnik V. Vaccination of volunteers was conducted as part of double-blind, randomized, placebo-controlled clinical trials in eight medical institutions selected as research centers in Belarus…

Milestones :: Perspectives :: Research

Chnia: COVID-19 Vaccines – Regulatory Actions/Deployment

Sinopharm News
China grants conditional market approval for Sinopharm CNBG’s COVID-19 Vaccine
Post Time:2021-01-02
The inactivated COVID-19 vaccine developed by Beijing Institute of Biological Products of Sinopharm CNBG has been granted conditional registration by the NMPA of China, Chinese equivalent of FDA, according to a press conference of the State Council Joint Prevention and Control Mechanism on December 31, 2020.

Over 60,000 volunteers of 125 nationalities have participated in the Phase III clinical trial of Sinopharm CNBG in countries outside China including UAE and Bahrain. The vaccine’s efficacy rate based on interim analysis is higher than the target set at the beginning, and its safety and effectiveness performances also exceed the standard level of both WHO for market approval and the Chinese regulatory authority for conditional market approval, which entitles the vaccine a general public use in China.

Aside from China, Sinopharm CNBG’s COVID-19 vaccine was announced to be officially registered in UAE and Bahrain on December 9 and 12 respectively, based on the results of Phase III clinical trials indicating 86% efficacy rate, 99 % seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of COVID-19.

Because the standards of diagnosis of infection cases and review process of Phase III clinical trial vary in different countries, the 86% efficacy rate announced by UAE and 79.34% by China are both real and valid.

A vaccine against COVID-19 should be evaluated comprehensively in various aspects such as safety, effectiveness, accessibility and affordability. Safety is undoubtedly the premise, on which the performance in effectiveness also matters to a large extent. Others including manufacturing capacity, storage and logistics conditions, targeted population should also be considered.

Generally speaking, Sinopharm CNBG’s COVID-19 vaccine has shown comprehensive strengths. A large sample of injection and data prove its safety and effectiveness. Besides, the vaccine doesn’t require freezing temperatures for storage, making transport and distribution much easier for most of the countries in the world. Its capacity is also large enough for massive inoculation.

The Chinese approved COVID-19 vaccine adds to the world’s faith in beating the pandemic. As defined by the Chinese government to be a global public good, Sinopharm CNBG COVID-19 vaccine will make its own contribution to the global fight against the coronavirus disease in the future.

::::::

National Health Commission of the People’s Republic of China [to 2 Jan 2021]
http://en.nhc.gov.cn/
News
Emergency use of COVID-19 vaccines expands to larger scale
Updated: 2020-12-31 | Xinhua
— The emergency use of vaccine mainly targets groups of people with higher risks of infection. They include medical workers, customs officers, primary-level epidemic prevention workers, overseas returnees and people working in cross-border cold-chain logistics and isolation centers.
— Experts remind people that they should still take protective measures after receiving the vaccination.

BEIJING — With the recent increase of sporadic COVID-19 cases and progress in the development and manufacture of vaccines, China’s emergency use of vaccines has expanded to a larger scale.

Inoculation of key groups has already started in Shanghai, Guangdong, Jiangxi, Shandong and the city of Wuhan in central China’s Hubei province. Many other provinces and municipalities have also drafted a schedule for COVID-19 vaccination in the coming months.
China granted emergency use of COVID-19 vaccines in June.

The emergency use of vaccine mainly targets groups of people with higher risks of infection. They include medical workers, customs officers, primary-level epidemic prevention workers, overseas returnees and people working in cross-border cold-chain logistics and isolation centers.

The southern Chinese city of Shenzhen began on Monday inoculating people who have urgent plans to travel overseas…

…In Guangdong Province, over 180,000 people had been given COVID-19 vaccines as of Dec 22, according to the provincial government. No serious side effects have been reported among the vaccine receivers, said the information office of the provincial government of Guangdong.

Wuhan, a city previously hit hard by the novel coronavirus, also started the emergency use of COVID-19 vaccines, with vaccinations available at 48 designated clinics in 15 districts starting from Dec 24…

::::::

National Medical Products Administration [to 2 Jan 2021]
http://english.nmpa.gov.cn/news.html
News
Chinese COVID-19 vaccines free to all its citizens: official
2020-12-31
China will provide COVID-19 vaccines free of charge to all its citizens, said Zeng Yixin, deputy head of the National Health Commission, at a press conference on Dec 31.

China grants conditional approval for first COVID vaccine
2020-12-31
China announced it has granted conditional market approval for its first COVID-19 vaccine during a news conference on Dec 31.
The vaccine, developed by State-owned Sinopharm, was approved by China’s top drug regulator on Wednesday night, said Chen Shifei, deputy head of the National Medical Products Administration.
The vaccine is generally safe and has a 79.34 percent efficacy rate according to clinical results released by the company on Wednesday. Strict supervision will continue to be carried out over the vaccine after its approval to ensure its safety and quality, Chen said.
A total of 14 COVID-19 vaccines developed by China are now under clinical trials, including five under phase-3 trials.
Before the official approval of the vaccine, the vaccine and several other COVID-19 vaccines in phase-3 clinical trials have already been put into emergency use in China over the past few months. Millions of doses have been used for priority groups such as frontline medical workers and people going overseas to work, and the safety and efficacy of the vaccines have been proved, said Zeng Yixin, vice-minister in charge of the National Health Commission.

Sinopharm’s vaccine shows protection rate of over 79%
2020-12-30
Sinopharm’s COVID-19 vaccine can induce neutralizing antibody in 99.52 percent of recipients, and has a 79.34 percent efficacy rate, according to midterm clinical results released on Dec 30.
The inactivated vaccine candidate created by Sinopharm’s Beijing Biological Products Institute is generally safe, and a high level of neutralizing antibodies can be detected in 99.52 percent of the recipients after two doses, the company said in a statement on Wednesday.
The vaccine is also 79.34 percent effective at preventing the symptoms of COVID-19, meaning it has met the requirement by the World Health Organization and the National Medical Products Administration. Now, the company has officially submitted its request for market approval to the administration, it said.

China’s Wuhan begins emergency-use COVID-19 vaccination
2020-12-29
WUHAN — The city of Wuhan in central China has started the emergency use of COVID-19 vaccine candidates on certain key groups of people, the municipal government said on Dec 28.
The vaccination, available at 48 designated clinics in 15 districts, began on Dec 24, targeting some key groups of people aged between 18 and 59, said He Zhenyu, deputy director of the center for disease control and prevention in Wuhan, capital of Hubei province.
Those receiving the vaccine need to take two shots with an interval of four weeks, said He at a press briefing…

Milestones :: Perspectives :: Research

Gavi [to 2 Jan 2021]
https://www.gavi.org/
News releases
Gavi welcomes final approval of U.S. support for global immunisation in Year-End Omnibus and COVID Supplemental Package
Geneva, 28 December 2020
:: The United States has approved US$ 4 billion for Gavi, the Vaccine Alliance to ensure lower-income economies have equitable access to safe and effective COVID-19 vaccines on the same urgent timeline as wealthier countries. These funds will help end this acute phase of the pandemic.
:: The United States also approved its Fiscal Year 2021 contribution of US$ 290 million for Gavi’s routine immunisation programmes. This funding is part of the multi-year pledge made to Gavi at the Global Vaccine Summit in June and will help provide life-saving vaccines to nearly half the world’s children.
:: Seth Berkley, CEO of Gavi: “This support from the American people will help Gavi procure and deliver COVID-19 vaccine doses for lower-income economies through the Gavi COVAX AMC. It will also shorten this crisis, save lives and help restart the global economy. In today’s interconnected world, no one is safe until everyone is safe.”

EMERGENCIES

Coronavirus [COVID-19]
Public Health Emergency of International Concern (PHEIC)

Weekly Epidemiological and Operational updates
Last update: 2 January 2021, 8:34 am GMT-5
Confirmed cases :: 82 356 727 [week ago: 78 604 532] [two weeks ago: 74 299 042]
Confirmed deaths :: 1 815 433 [week ago: 1 744 235] [two weeks ago: 1 669 982]
Countries, areas or territories with cases :: 222

::::::

WHO Director-General’s opening remarks at the media briefing on COVID-19
28 December 2020

Weekly epidemiological update – 29 December 2020
Overview
Globally in the past week, over 4 million new COVID-19 cases and 72 000 new deaths were reported. This brings the cumulative numbers to over 79 million reported cases and over 1.7 million deaths globally since the start of the pandemic.

::::::
::::::

Emergencies

POLIO
Public Health Emergency of International Concern (PHEIC)

Polio this week as of 30 December 2020

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):
:: Afghanistan: one WPV1 positive environmental sample and 26 cVDPV2 cases
:: Pakistan: five WPV1 positive environmental samples
:: Nigeria: one cVDPV2 case and two cVDPV2 positive environmental samples
:: Guinea: seven cVDPV2 cases
:: Liberia: two cVDPV2 positive environmental samples
:: Sierra Leone: three cVDPV2 cases

::::::
::::::

Editor’s Note:
With this edition, we add information about the last apparent update evident on the WHO emergency webpage, recognizing significant interims regardless of the level of the emergency listed.

WHO Grade 3 Emergencies [to 2 Jan 2021]

Democratic Republic of the Congo – No new digest announcements identified [Last apparent update: 15 October 2020]
Mozambique floods – No new digest announcements identified [Last apparent update: 3 November 2020]
Nigeria – No new digest announcements identified [Last apparent update: 29 Jun 2020]
Somalia – No new digest announcements identified [Last apparent update: 17 July 2020]
South Sudan – No new digest announcements identified [Last apparent update: 4 February 2020]
Syrian Arab Republic – No new digest announcements identified [Last apparent update: 24 October 2020]
Yemen – No new digest announcements identified [Last apparent update: 30 June 2020]

::::::

WHO Grade 2 Emergencies [to 2 Jan 2021]
Myanmar
:: 24 December 2020 News release
Bangladesh gradually resumes essential health services delivery disrupted due to the COVID-19 pandemic

Afghanistan – No new digest announcements identified [Last apparent update: 5 July 2020]
Angola – No new digest announcements identified [Last apparent update: 03 December 2020]
Burkina Faso – No new digest announcements identified [Last apparent update: 17 décembre 2020]
Burundi – No new digest announcements identified [Last apparent update: 04 July 2019]
Cameroon – No new digest announcements identified [Last apparent update: 22 August 2019]
Central African Republic – No new digest announcements identified [Last apparent update: 12 June 2018]
Ethiopia – No new digest announcements identified [Last apparent update: 22 August 2019]
Iran floods 2019 – No new digest announcements identified [Last apparent update: 12 March 2020]
Iraq – No new digest announcements identified [Last apparent update: 16 December 2020]
Libya – No new digest announcements identified [Last apparent update: 7 October 2019]
Malawi Floods – No new digest announcements identified [Last apparent update: 09 October 2019]
Measles in Europe – No new digest announcements identified [Last apparent update: 16-12-2020]
MERS-CoV – No new digest announcements identified [Last apparent update: 8 July 2019]
Mozambique – No new digest announcements identified [Last apparent update: 03 November 2020]
Niger – No new digest announcements identified [Last apparent update: 24 December 2020]
occupied Palestinian territory – No new digest announcements identified [Last apparent update: 4 September 2019]
HIV in Pakistan – No new digest announcements identified [Last apparent update: 27 August 2019]
Sao Tome and Principe Necrotizing Cellulitis (2017) – No new digest announcements
Sudan – No new digest announcements identified [Last apparent update: 24 June 2020]
Ukraine – No new digest announcements identified [Last apparent update: 1 May 2019]
Zimbabwe – No new digest announcements identified [Last apparent update: 10 May 2019]

::::::

WHO Grade 1 Emergencies [to 2 Jan 2021]

Chad – No new digest announcements identified [Last apparent update: 30 June 2018]
Djibouti – No new digest announcements identified [Last apparent update: 25 novembre 2020]
Kenya – No new digest announcements identified [Last apparent update: 11 December 2020]
Mali – No new digest announcements identified [Last apparent update: 3 May 2017]
Namibia – viral hepatitis – No new digest announcements identified [Last apparent update: 20 July 2018]
Tanzania – No new digest announcements identified [Last apparent update: 21 October 2020]

::::::
::::::

UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 
Syrian Arab Republic – No new digest announcements identified
Yemen – No new digest announcements identified

::::::

UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.
COVID-19
:: Coronavirus Disease (COVID-19): Weekly Epidemiological Update (29 December 2020)

East Africa Locust Infestation
:: Desert Locust situation update – 30 December 2020

::::::
::::::

WHO & Regional Offices [to 2 Jan 2021]
31 December 2020 News release
WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access
[See Milestones above for detail]

30 December 2020 Statement
COVID-19: One year later – WHO Director-General’s new year message

::::::

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: WHO urges greater surveillance as new COVID-19 variants emerge
30 December 2020 Brazzaville – With the recent emergence in the African region of new COVID-19 variants which seem to have higher transmissibility, the World Health Organization (WHO) calls on countries to boost genomic surveillance and analysis through the African genome sequencing laboratory network to detect any new mutations and strengthen the efforts to curb the pandemic…

WHO Region of the Americas PAHO
No new digest content identified

WHO South-East Asia Region SEARO
No new digest content identified

WHO European Region EURO
:: Can people afford to pay for health care? New report considers status of universal health coverage in the Republic of Moldova 28-12-2020

WHO Eastern Mediterranean Region EMRO::
:: Meeting exceptional challenges together 28 December 2020 [Dr Ahmed Al-Mandhari, WHO Regional Director for the Eastern Mediterranean]

WHO Western Pacific Region
No new digest content identified

CDC/ACIP [to 2 Jan 2021]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Latest News Releases, Announcements
Transcript: CDC Update on COVID-19
Wednesday, December 30, 2020
… THANK YOU EVERYONE WHO HAS JOINS US TO DISCUSS TWO, NEW VARIANTS OF THE VIRUS THAT CAUSES COVID-19 AS WELL AS COVID-19 VACCINES.  WE ARE JOINED BY DR. HENRY WALKE, THE INCIDENT MANAGER FOR CDC’S COVID-19 RESPONSE AND DR.  NANCY MESSONNIER, DIRECTOR CDC’S NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES,  AND THE SENIOR FEDERAL OFFICIAL LEADING THE AGENCY’S VACCINE EFFORTS. 

CDC 2020 in Review
Tuesday, December 29, 2020
In 2020 CDC worked around the clock – and around the globe – to protect Americans from health threats. While the COVID-19 pandemic has dominated the news, a number of other public health and scientific advancements are worth highlighting.
“This has been a year of challenges, but also of innovation, modernization, and advancement in public health,” said Dr. Robert R. Redfield, CDC Director. “I am hopeful for the future and the months to come as CDC continues to secure the safety of the American people and this Nation.”…

Coronavirus Disease 2019 (COVID-19)
Selected Resources
:: Information about the Moderna COVID-19 Vaccine
Friday, January 01, 2021

:: Information about the Pfizer-BioNTech COVID-19 Vaccine
Friday, January 01, 2021

:: Impact of COVID-19 Pandemic on Global Poliovirus Surveillance
Thursday, December 31, 2020

:: The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 Vaccine – United States, December 2020
Thursday, December 31, 2020

:: The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine – United States, December 2020
Thursday, December 31, 2020

:: When Vaccine is Limited, Who Gets Vaccinated First?

Thursday, December 31, 2020
:: How CDC Is Making COVID-19 Vaccine Recommendations
Wednesday, December 30, 2020

:: The Importance of COVID-19 Vaccination for Healthcare Personnel
Monday, December 28, 2020

:: Importance of COVID-19 Vaccination for Residents of Long-term Care Facilities
Monday, December 28, 2020

Africa CDC [to 2 Jan 2021]
http://www.africacdc.org/
News
No new digest content identified.

China CDC
http://www.chinacdc.cn/en/
No new digest content identified.

National Health Commission of the People’s Republic of China [to 2 Jan 2021]
http://en.nhc.gov.cn/
News
Jan 2: Daily briefing on novel coronavirus cases in China
On Jan 1, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 22 new cases of confirmed infections.

Emergency use of COVID-19 vaccines expands to larger scale
Updated: 2020-12-31 | Xinhua

National Medical Products Administration [to 2 Jan 2021]
http://english.nmpa.gov.cn/news.html
News
Chinese mainland reports 9 new locally transmitted COVID-19 cases
2020-12-31
The Chinese mainland on Wednesday reported 25 newly confirmed COVID-19 cases, including nine locally transmitted cases and 16 arriving from outside the mainland, the National Health Commission said on Dec 31.

Chinese COVID-19 vaccines free to all its citizens: official
2020-12-31
China will provide COVID-19 vaccines free of charge to all its citizens, said Zeng Yixin, deputy head of the National Health Commission, at a press conference on Dec 31.

China grants conditional approval for first COVID vaccine
2020-12-31
China announced it has granted conditional market approval for its first COVID-19 vaccine during a news conference on Dec 31.

Sinopharm’s vaccine shows protection rate of over 79%
2020-12-30
Sinopharm’s COVID-19 vaccine can induce neutralizing antibody in 99.52 percent of recipients, and has a 79.34 percent efficacy rate, according to midterm clinical results released on Dec 30.

China’s Wuhan begins emergency-use COVID-19 vaccination
2020-12-29
The city of Wuhan in central China has started the emergency use of COVID-19 vaccine candidates on certain key groups of people, the municipal government said on Dec 28.

Announcements

Paul G. Allen Frontiers Group [to 2 Jan 2021]
https://alleninstitute.org/what-we-do/frontiers-group/news-press/
News
No new digest content identified.

BARDA – U.S. Department of HHS [to 2 Jan 2021]
https://www.phe.gov/about/barda/Pages/default.aspx
BARDA News
No new digest content identified.

BMGF – Gates Foundation [to 2 Jan 2021]
http://www.gatesfoundation.org/Media-Center/Press-Releases
Press Releases and Statements
No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 2 Jan 2021]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

CARB-X [to 2 Jan 2021]
https://carb-x.org/
News
No new digest content identified.

Center for Vaccine Ethics and Policy [to 2 Jan 2021]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
An Informed Choice/Consent/Right-to-Refuse Imperative :: Statement on Immunization Involving COVID-19 Vaccines Under Emergency Use Authorization/Listing [EUA/L]
1 January 2021 The GE2P2 Global Foundation’s Center for Vaccine Ethics and Policy has developed a statement that argues that immunization involving COVID-19 vaccines available under emergency use mechanisms or expanded access/compassionate use triggers an imperative to assure that individuals receive the information required to support free exercise of meaningful informed choice/consent, with a right to refuse such vaccination for any reason or no reason. The full statement is available here: http://www.ge2p2.org/the-informed-choice/consent/right-to-refuse-imperative

CEPI – Coalition for Epidemic Preparedness Innovations [to 2 Jan 2021]
http://cepi.net/
Latest News
CEPI-supported COVID-19 vaccine, developed by University of Oxford/ AstraZeneca, receives authorisation in the UK
30 Dec 2020
Statement from Dr. Richard Hatchett, CEO of CEPI, welcoming the announcement from the UK’s independent regulatory authority, MHRA:
“We were delighted to hear today’s (30 December) announcement that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted emergency authorisation for the University of Oxford/AstraZeneca COVID-19 vaccine.
“MHRA’s determination that the University of Oxford/AstraZeneca COVID-19 vaccine is safe and effective paves the way, we hope, for similar determinations by other stringent regulatory authorities and for WHO Prequalification in the days and weeks ahead.
“The Oxford/AstraZeneca COVID-19 vaccine is extremely attractive in that it is inexpensive, scalable, and can be stored at 2-8 degrees Celsius. These attributes will enable its use worldwide, including in low-income and middle-income countries, alongside other safe and effective COVID-19 vaccines, and the large supplies that will become available in 2021 mean that this vaccine could be a gamechanger in terms of our efforts to end the acute phase of the pandemic.
“Today’s authorization of a vaccine based on viral vector technology, as opposed to the mRNA approach employed by the Pfizer and Moderna vaccines, solidifies our belief that we will soon have a diverse array of vaccines with which to fight this devastating pandemic.

CEPI partners with Biological E Limited to advance development and manufacture of COVID-19 vaccine candidate
29 December 2020, Oslo, Norway and Hyderabad, India—
CEPI, the Coalition for Epidemic Preparedness Innovations and Biological E Limited, India (Bio E), a Hyderabad-based vaccines and pharmaceutical company, today announced a collaboration to advance the development and manufacture of Bio E’s COVID-19 subunit vaccine candidate. CEPI will initially contribute up to $5m toward the cost of scaling up the process for manufacturing the vaccine, and will explore providing additional funding to Bio E with the goal of potentially enabling the production of 100 million doses in 2021. The candidate has also received seed funding from Department of Biotechnology, Govt of India…

EDCTP [to 2 Jan 2021]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

Emory Vaccine Center [to 2 Jan 2021]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Medicines Agency [to 2 Jan 2021]
http://www.ema.europa.eu/ema/
News & Press Releases
Update on rolling review of AstraZeneca’s COVID-19 vaccine
News 30/12/2020
EMA’s assessment of the COVID-19 vaccine being developed by AstraZeneca and Oxford University has been progressing over the past weeks. The Agency is currently assessing data on the vaccine as part of a rolling review.
So far, some evidence has been assessed on safety and efficacy coming from a pooled analysis of interim clinical data from four ongoing clinical trials in the UK, Brazil and South Africa. The latest clinical package was received on 21 December and is currently being assessed. CHMP has already assessed data from laboratory studies (non-clinical data) and is currently assessing data on the vaccine’s quality (on its ingredients and the way it is manufactured).
Additional scientific information on issues related to quality, safety and efficacy of the vaccine is deemed necessary to support the rigour required for a conditional marketing authorisation and this has been requested from the company.
Further information from the ongoing clinical trials is also expected from January. Interim data from a large trial ongoing in the USA are expected in Q1 2021.
EMA is aware that the UK MHRA has granted a temporary authorisation of supply of the vaccine in the emergency use setting, which is distinct from a marketing authorisation. EMA, its European experts and the European Commission are working towards conditional marketing authorisation of COVID-19 vaccines, with all the safeguards, controls and obligations that this imposes. It guarantees that the vaccine meets rigorous EU standards for safety, efficacy and quality…

European Vaccine Initiative [to 2 Jan 2021]
http://www.euvaccine.eu/
Latest News
Website not responding at inquiry

FDA [to 2 Jan 2021]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
Press Announcements /Selected Details
December 30, 2020 – Coronavirus (COVID-19) Update: December 30, 2020

December 28, 2020 – Coronavirus (COVID-19) Update: December 28, 2020

FDA – COVID-19 Vaccines [to 2 Jan 2021]
www.fda.gov/covid19vaccines
News and Updates; Upcoming Events
12/28/2020
Coronavirus (COVID-19) Update
The FDA posts an updated letter of authorization, health care provider fact sheet and frequently asked questions regarding the number of Pfizer-BioNTech doses in a vial, updated the Device Shortage List, and provides a testing update.

12/28/2020
Video Discussion: COVID-19 VaccinesExternal Link Disclaimer
In this 30-minute video discussion, FDA Commissioner Dr. Stephen Hahn and Center for Biologics Evaluation and Research (CBER) Director Dr. Peter Marks talk with WebMD about what we know, what we don’t know, and what we might learn in the future about COVID-19 vaccines.

Fondation Merieux [to 2 Jan 2021]
http://www.fondation-merieux.org/
News, Events
Press Releases
No new digest content identified.

Gavi [to 2 Jan 2021]
https://www.gavi.org/
News releases
Gavi welcomes final approval of U.S. support for global immunisation in Year-End Omnibus and COVID Supplemental Package
Geneva, 28 December 2020
See Milestones above for detail

GHIT Fund [to 2 Jan 2021]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 212 with the aim of developing new tools to tackle infectious diseases that
Press Releases
No new digest content identified.

Global Fund [to 2 Jan 2021]
https://www.theglobalfund.org/en/news/
News
No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 2 Jan 2021]
https://www.glopid-r.org/news/
News
No new digest content identified.

Hilleman Laboratories [to 2 Jan 2021]
http://www.hillemanlabs.org/
No new digest content identified.

Human Vaccines Project [to 2 Jan 2021]
http://www.humanvaccinesproject.org/media/press-releases/
Press Releases
No new digest content identified.

IAVI [to 2 Jan 2021]
https://www.iavi.org/newsroom
PRESS RELEASES/FEATURES
No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest content identified.

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

IFRC [to 2 Jan 2021]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
No new digest content identified.

Institut Pasteur [to 2 Jan 2021]
https://www.pasteur.fr/en/press-area
Press documents
No new digest content identified.

IRC International Rescue Committee [to 2 Jan 2021]
http://www.rescue.org/press-release-index
Media highlights [Selected]
No new digest content identified.

IVAC [to 2 Jan 2021]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
No new digest content identified.

IVI [to 2 Jan 2021]
http://www.ivi.int/
Selected IVI News, Announcements, Events
No new digest content identified.

JEE Alliance [to 2 Jan 2021]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

Johns Hopkins Center for Health Security [to 2 Jan 2021]
https://www.centerforhealthsecurity.org/news/center-news/
Center News
No new digest content identified.

MSF/Médecins Sans Frontières [to 2 Jan 2021]
http://www.msf.org/
Latest [Selected Announcements]
No new digest content identified.

National Vaccine Program Office – U.S. HHS [to 2 Jan 2021]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
No new digest content identified.

NIH [to 2 Jan 2021]
http://www.nih.gov/news-events/news-releases
News Releases
Peer-reviewed report on Moderna COVID-19 vaccine publishes
December 30, 2020 — Data from Phase 3 clinical trial confirm vaccine is effective.
LR Baden, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England Journal of Medicine. DOI: 10.1056/NEJMoa2035389.

NIH study uncovers blood vessel damage and inflammation in COVID-19 patients’ brains but no infection
December 30, 2020 — Results from a study of 19 deceased patients suggests brain damage is a byproduct of a patient’s illness.
In an in-depth study of how COVID-19 affects a patient’s brain, National Institutes of Health researchers consistently spotted hallmarks of damage caused by thinning and leaky brain blood vessels in tissue samples from patients who died shortly after contracting the disease. In addition, they saw no signs of SARS-CoV-2 in the tissue samples, suggesting the damage was not caused by a direct viral attack on the brain. The results were published as a correspondence in the New England Journal of Medicine…

Phase 3 trial of Novavax investigational COVID-19 vaccine opens
December 28, 2020 — NIH- and BARDA-funded trial will enroll up to 30,000 volunteers.
People 18 years of age and older who are interested in participating in this trial can visit coronaviruspreventionnetwork.org(link is external), ClinicalTrials.gov and search identifier NCT04611802, or Novavax.com/PREVENT-19(link is external) for details. Please do not contact the NIAID media phone number or email to enroll in this trial.

PATH [to 2 Jan 2021]
https://www.path.org/media-center/
Press Release
No new digest content identified.

Sabin Vaccine Institute [to 2 Jan 2021]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

UNAIDS [to 2 Jan 2021]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
No new digest content identified.

UNICEF [to 2 Jan 2021]
https://www.unicef.org/media/press-releases
Selected Press releases, Statements
Press release
12/31/2020
New Year’s Babies: Over 370,000 children will be born worldwide on New Year’s Day – UNICEF
With the calendar flipping to 2021, UNICEF dedicates its 75th year to reimagining a better world for children.

Press release
12/30/2020
An estimated 10.4 million children in the Democratic Republic of the Congo, northeast Nigeria, the Central Sahel, South Sudan and Yemen will suffer from acute malnutrition in 2021
UNICEF warns numbers could rise further without urgent action

Unitaid [to 2 Jan 2021]
https://unitaid.org/
Featured News
No new digest content identified.

Vaccination Acceptance Research Network (VARN) [to 2 Jan 2021]
https://vaccineacceptance.org/news.html#header1-2r
Announcements
No new digest content identified.

Vaccine Confidence Project [to 2 Jan 2021]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 2 Jan 2021]
http://www.chop.edu/centers-programs/vaccine-education-center
News
No new digest content identified.

Wellcome Trust [to 2 Jan 2021]
https://wellcome.ac.uk/news
News
No new digest content identified.

The Wistar Institute [to 2 Jan 2021]
https://www.wistar.org/news/press-releases
Press Releases
No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 2 Jan 2021]
https://www.wfpha.org/
Latest News
No new digest content identified.

World Organisation for Animal Health (OIE) [to 2 Jan 2021]
https://www.oie.int/en/for-the-media/press-releases/2020/
No new digest content identified.

::::::

ARM [Alliance for Regenerative Medicine] [to 2 Jan 2021]
https://alliancerm.org/
Press Releases
No new digest content identified.

BIO [to 2 Jan 2021]
https://www.bio.org/press-releases
Press Releases
Injunction Placed on Punitive and Political Maneuver by Administration
December 29, 2020
A judge in the United States District Court for the Northern District of California yesterday issued a preliminary injunction blocking the Administration’s “Most Favored Nation” reimbursement policy for certain drugs administered by Medicare Part B…

DCVMN – Developing Country Vaccine Manufacturers Network [to 2 Jan 2021]
http://www.dcvmn.org/
News; Upcoming events
First Sabin Inactivated Poliovirus Vaccine (sIPV) Achieved WHO Prequalification
Geneva, 21st December 2020

ICBA – International Council of Biotechnology Associations [to 2 Jan 2021]
https://internationalbiotech.org/news/
News
No new digest content identified.

IFPMA [to 2 Jan 2021]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
No new digest content identified.

PhRMA [to 2 Jan 2021]
http://www.phrma.org/
Selected Press Releases, Statements
No new digest content identified.

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focu-s on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AMA Journal of Ethics
Volume 22, Number 12: E981-1070
https://journalofethics.ama-assn.org/issue/socially-situated-brain-death

Socially Situated Brain Death
In 1980, the Uniform Determination of Death Act (UDDA) defined death as “(1) irreversible cessation of circulatory and respiratory functions, or (2) irreversible cessation of all functions of the entire brain, including the brain stem … in accordance with accepted medical standards.” Interpreting the UDDA definition and applying neurological criteria for diagnosing brain death sound straightforward. Brain death is, however, socially situated, not observer independent, and fraught with uncertainty and ambiguity. This issue investigates some of the ethical, cultural, and legal complexities of one of medicine’s most critical tasks: being sharp and sure about who is alive and who is dead.
Full Issue PDF

American Journal of Infection Control
January 2021 Volume 49 Issue 1 p1-136
http://www.ajicjournal.org/current

Major Articles
Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19
Beatriz Böger, Mariana M. Fachi, Raquel O. Vilhena, Alexandre F. Cobre, Fernanda S. Tonin, Roberto Pontarolo
Published online: July 09, 2020
p21-29

American Journal of Infection Control
January 2021 Volume 49 Issue 1 p1-136
http://www.ajicjournal.org/current

State of the Science Review
A systematic review of chlorine-based surface disinfection efficacy to inform recommendations for low-resource outbreak settings
Karin Gallandat, Riley C. Kolus, Timothy R. Julian, Daniele S. Lantagne
Published online: May 19, 2020
p90-103
Open Access

American Journal of Preventive Medicine
January 2021 Volume 60 Issue 1 p1-150
http://www.ajpmonline.org/current

Current Issues
The Impact of Public Health Organization and Political Figure Message Sources on Reactions to Coronavirus Prevention Messages
Marcella H. Boynton, Ross E. O’Hara, Howard Tennen,
Joseph G.L. Lee
Published online: August 27, 2020
p136-138

American Journal of Public Health
December 2020 110(12)
http://ajph.aphapublications.org/toc/ajph/current

STUDENT PERSPECTIVES ON COVID-19
Human Rights Advocacy and Us, the Next Generation of Public Health Leaders
Human Rights, Social Science, Public Health Practice
Hanna E. Huffstetler, Tamira Daniely, Meredith Dockery, Tsion Ghedamu, Lenore Hango, Ashley Huff, Victoria Matus, Hannah Rice, Sonam J. Shah, Sonam K. Shah, Niharika Soni and Caitlin R. Williams
111(1), pp. 74–76

American Journal of Public Health
December 2020 110(12)
http://ajph.aphapublications.org/toc/ajph/current

INTERSECTIONALITY
Artificial Intelligence, Intersectionality, and the Future of Public Health
Other Race/Ethnicity, Human Rights, Statistics/Evaluation/Research, Epidemiology, Ethics, Race/Ethnicity, Gender, Other Statistics/Evaluation/Research
Greta R. Bauer and Daniel J. Lizotte
111(1), pp. 98–100

American Journal of Public Health
December 2020 110(12)
http://ajph.aphapublications.org/toc/ajph/current

LAW & ETHICS
Preventing the Spread of COVID-19 in Immigration Detention Centers Requires the Release of Detainees
William D. Lopez, Nolan Kline, Alana M. W. LeBrón, Nicole L. Novak, Maria-Elena De Trinidad Young, Gregg Gonsalves, Ranit Mishori, Basil A. Safi and Ian M. Kysel
111(1), pp. 110–115

The European Journal of Public Health
Volume 30, Issue 6, December 2020
https://academic.oup.com/eurpub/issue/30/6

Editorial
Equitable access to COVID-19 vaccination: a distant dream?
M Lomazzi, L De Sousa, G Amofah, W Ricciardi
European Journal of Public Health, Volume 30, Issue 6, December 2020, Pages 1039–1040, https://doi.org/10.1093/eurpub/ckaa190

Expert Review of Vaccines
Vol 19 (11) 2020
https://www.tandfonline.com/toc/ierv20/current

Editorial
Restoring confidence in vaccines in the COVID-19 era
Pierre Verger & Eve Dubé
Pages: 991-993
Published online: 08 Oct 2020

Expert Review of Vaccines
Vol 19 (11) 2020
https://www.tandfonline.com/toc/ierv20/current

Review
The status of human papillomavirus vaccination recommendation, funding, and coverage in WHO Europe countries (2018–2019)
Paolo Bonanni, Pascaline Faivre, Pier Luigi Lopalco, Elmar A. Joura, Tobias Bergroth, Stefan Varga, Nathalie Gemayel & Rosybel Drury
Pages: 1073-1083
Published online: 14 Dec 2020

Expert Review of Vaccines
Vol 19 (11) 2020
https://www.tandfonline.com/toc/ierv20/current

Vaccine strategies to reduce the burden of pneumococcal disease in HIV-infected adults in Africa.
Deus Thindwa, Amy Pinsent, John Ojal, Katherine E Gallagher, Neil French & Stefan Flasche
Pages: 1085-1092
Published online: 03 Dec 2020

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 2 Jan 2021]

Statistical power in COVID-19 case-control host genomic study design
The identification of genetic variation that directly impacts infection susceptibility to SARS-CoV-2 and disease severity of COVID-19 is an important step towards risk stratification, personalized treatment pl…
Authors: Yu-Chung Lin, Jennifer D. Brooks, Shelley B. Bull, France Gagnon, Celia M. T. Greenwood, Rayjean J. Hung, Jerald Lawless, Andrew D. Paterson, Lei Sun and Lisa J. Strug
Citation: Genome Medicine 2020 12:115
Content type: Correspondence
Published on: 28 December 2020

Global Health Action
Volume 14, Issue 1 (2021)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList

Article
Characterizing ‘health equity’ as a national health sector priority for maternal, newborn, and child health in Ethiopia
Nicole Bergen, Arne Ruckert, Lakew Abebe, Shifera Asfaw, Getachew Kiros, Abebe Mamo, Sudhakar Morankar, Manisha A. Kulkarni & Ronald Labonté
Article: 1853386
Published online: 30 Dec 2020

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 2 Jan 2021]

Research
Integrating the social sciences in epidemic preparedness and response: A strategic framework to strengthen capacities and improve Global Health security
Authors: Kevin Louis Bardosh, Daniel H. de Vries, Sharon Abramowitz, Adama Thorlie, Lianne Cremers, John Kinsman and Darryl Stellmach
30 December 2020

Health Affairs
Vol. 39, No. 12 December 2020
https://www.healthaffairs.org/toc/hlthaff/current

Climate & Health
Analysis Environmental Health
Valuing Health Impacts In Climate Policy: Ethical Issues And Economic Challenges
Noah Scovronick, Maddalena Ferranna, Francis Dennig, and Mark Budolfson
2105-2112

Humanitarian Exchange Magazine
Number 78, October 2020
https://odihpn.org/magazine/inclusion-of-persons-with-disabilities-in-humanitarian-action-what-now/

Disability inclusion in humanitarian action
by HPN October 2020
The theme of this edition of Humanitarian Exchange, co-edited with Sherin Alsheikh Ahmed from Islamic Relief Worldwide, is disability inclusion in humanitarian action. Persons with disabilities are not only disproportionately impacted by conflicts, disasters and other emergencies, but also face barriers to accessing humanitarian assistance. At the same time, global commitments and standards and the IASC Guidelines on the inclusion of persons with disabilities in humanitarian action all emphasise how persons with disabilities are also active agents of change. Disability and age-focused organisations have led on testing and demonstrating how inclusion can be done better. Yet despite this progress, challenges to effective inclusion remain.

As Kirstin Lange notes in the lead article, chief among these challenges is humanitarian agencies’ lack of engagement with organisations of persons with disabilities. Simione Bula, Elizabeth Morgan and Teresa Thomson look at disability inclusion in humanitarian response in the Pacific, and Kathy Al Jubeh and Alradi Abdalla argue for a ‘participation revolution’, building on learning from the gender movement. Tchaurea Fleury and Sulayman AbdulMumuni Ujah outline how the Bridge Article 11 training initiative is encouraging constructive exchange between humanitarian and disability actors. The lack of good, disaggregated data is highlighted by Sarah Collinson; Frances Hill, Jim Cranshaw and Carys Hughes emphasise the need for training resources in local languages and accessible formats; and Sophie Van Eetvelt and colleagues report on a review of the evidence on inclusion of people with disabilities and older people.

Rebecca Molyneux and co-authors analyse the findings of a review of a DFID programme in north-east Nigeria, while Carolin Funke highlights the importance of strategic partnerships between disability-focused organisations, drawing on her research in Cox’s Bazar. Sherin Alsheikh Ahmed describes Islamic Relief Worldwide’s approach to mainstreaming protection and inclusion, while Pauline Thivillier and Valentina Shafina outline IRC’s Client Responsive Programming. The edition ends with reflections by Mirela Turcanu and Yves Ngunzi Kahashi on CAFOD’s SADI approach.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 16, Issue 11, 2020
http://www.tandfonline.com/toc/khvi20/current

Article
Social media and vaccine hesitancy: new updates for the era of COVID-19 and globalized infectious diseases
Neha Puri, Eric A. Coomes, Hourmazd Haghbayan & Keith Gunaratne
Pages: 2586-2593
Published online: 21 Jul 2020

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 16, Issue 11, 2020
http://www.tandfonline.com/toc/khvi20/current

Article commentary
Impact of COVID-19 on vaccination programs: adverse or positive?
Inayat Ali
Pages: 2594-2600
Published online: 22 Sep 2020

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 16, Issue 11, 2020
http://www.tandfonline.com/toc/khvi20/current

Pertussis in high-risk groups: an overview of the past quarter-century
Victoria A Jenkins, Miloje Savic & Walid Kandeil
Pages: 2609-2617
Published online: 16 Apr 2020

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 16, Issue 11, 2020
http://www.tandfonline.com/toc/khvi20/current

Article
Determinants of low uptake of vaccination against influenza, measles, and hepatitis B among healthcare professionals in Greece: a multicenter cross-sectional study
Olga Vrachnaki, Eleni Vergadi, Eleni Ioannidou & Emmanouil Galanakis
Pages: 2663-2669
Published online: 13 May 2020

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 16, Issue 11, 2020
http://www.tandfonline.com/toc/khvi20/current

article commentary
Dengue vaccines: the road to failure or to success?
Stanley A. Plotkin
Pages: 2677-2679
Published online: 19 May 2020
A licensed vaccine against dengue was shown to enhance disease under some circumstances, even though it protected most vaccinees. We discuss the implication of these results for the future of dengue vaccines.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 16, Issue 11, 2020
http://www.tandfonline.com/toc/khvi20/current

Article
HPV vaccine hesitancy among parents in Italy: a cross-sectional study
Giorgia Della Polla, Concetta Paola Pelullo, Francesco Napolitano & Italo Francesco Angelillo
Pages: 2744-2751
Published online: 16 Apr 2020

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 16, Issue 11, 2020
http://www.tandfonline.com/toc/khvi20/current

Review
Meningococcal infections among refugees and immigrants: silent threats of past, present and future
Ener Cagri Dinleyici & Ray Borrow on behalf of Global Meningococcal Initiative
Pages: 2781-2786
Published online: 29 Apr 2020

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 16, Issue 11, 2020
http://www.tandfonline.com/toc/khvi20/current

Review of long term immunogenicity and tolerability of live hepatitis A vaccine
Nitin Shah, MMA Faridi, Monjori Mitra, Ashish Bavdekar, Archana Karadkhele, Gaurav Puppalwar & Rishi Jain
Pages: 2816-2821
Published online: 03 Apr 2020

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 16, Issue 11, 2020
http://www.tandfonline.com/toc/khvi20/current

Article
Pathway towards an ideal and sustainable framework agreement for the public procurement of vaccines in Spain: a multi-criteria decision analysis
N. Zozaya González, B. Alcalá Revilla, P. Arrazola Martínez, J. R. Chávarri Bravo, I. Cuesta Esteve, A. J. García Rojas, F. Martinón-Torres, E. Redondo Margüello, A. Rivero Cuadrado, S. Tamames Gómez, J. Villaseca Carmena & A. Hidalgo-Vega
Pages: 2873-2884
Published online: 03 Apr 2020

JAMA Network
COVID-19 Update January 2, 2021

These articles on COVID-19 were published across the JAMA Network in the last week.
Selected Articles
Opinion
Mandating COVID-19 Vaccines
Lawrence O. Gostin, JD; Daniel A. Salmon, MPH, PhD; Heidi J. Larson, PhD
…From EUAs to BLA Approvals
Mandating COVID-19 vaccines under an EUA is legally and ethically problematic. The act authorizing the FDA to issue EUAs requires the secretary of the Department of Health and Human Services (HHS) to specify whether individuals may refuse the vaccine and the consequences for refusal. Vaccine mandates are unjustified because an EUA requires less safety and efficacy data than full Biologics License Application (BLA) approval. Individuals would also likely distrust vaccine mandates under emergency use, viewing it as ongoing medical research.
Should SARS-CoV-2 Vaccines Be Mandatory?
Once SARS-CoV-2 vaccines receive a BLA, policy makers must determine to which, if any, populations mandates should apply. Vaccine mandates could be imposed in multiple sectors, each with their own legal and ethical considerations…

JAMA Network
COVID-19 Update January 2, 2021

JAMA Health Forum
Opinion
Older Adults’ Perspectives on a COVID-19 Vaccine
Preeti N. Malani, MD, MSJ; Erica Solway, PhD, MSW, MPH; Jeffrey T. Kullgren, MD, MS, MPH

JAMA Network
COVID-19 Update January 2, 2021

Video
AMA Network Open Live
COVID-19 Vaccine Mandates
Emily A. Largent, JD, PhD, RN, joins JAMA Network Open Digital Media Editor, Seth Trueger, MD, MPH, to discuss a survey study assessing the acceptability of coronavirus disease 2019 vaccine mandates among members of the US public

Journal of Medical Ethics
January 2021 – Volume 47 – 1
http://jme.bmj.com/content/current

Covid 19 Current Controversies

Fair and equitable subject selection in concurrent COVID-19 clinical trials (12 October, 2020) Free
Maud O. Jansen, Peter Angelos, Stephen J. Schrantz, Jessica S. Donington, Maria Lucia L. Madariaga, Tanya L. Zakrison

Journal of Medical Ethics
January 2021 – Volume 47 – 1
http://jme.bmj.com/content/current

Covid 19 Current Controversies
Fair allocation of scarce medical resources in the time of COVID-19: what do people think? (12 October, 2020)
Francesco Fallucchi, Marco Faravelli, Simone Quercia

Journal of Pediatrics
January 2021 Volume 228 p1-326
http://www.jpeds.com/current

Original Articles
Willingness to Vaccinate Children against Influenza after the Coronavirus Disease 2019 Pandemic
Ran D. Goldman, Sophie McGregor, Shashidhar R. Marneni,…Samina Ali, Julie C. Brown
andfor the International COVID-19 Parental Attitude Study (COVIPAS) Group
Published online: August 06, 2020
p87-93.e2

The Lancet
Jan 02, 2021 Volume 397 Number 10268 p1-70, e1
https://www.thelancet.com/journals/lancet/issue/current

Editorial
Health as a foundation for society
The Lancet

The Lancet
Jan 02, 2021 Volume 397 Number 10268 p1-70, e1
https://www.thelancet.com/journals/lancet/issue/current

Comment
Poliovirus vaccine options: another step forward
Kimberly M Thompson

The Lancet
Jan 02, 2021 Volume 397 Number 10268 p1-70, e1
https://www.thelancet.com/journals/lancet/issue/current

The COVID-19 vaccines rush: participatory community engagement matters more than ever
Rochelle Ann Burgess, et al

The Lancet
Jan 02, 2021 Volume 397 Number 10268 p1-70, e1
https://www.thelancet.com/journals/lancet/issue/current

Articles
Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials
Xavier Sáez-Llorens, et al
Open Access

The Lancet
Jan 02, 2021 Volume 397 Number 10268 p1-70, e1
https://www.thelancet.com/journals/lancet/issue/current

Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials
Ilse De Coster, et al
Open Access

The Lancet
Jan 02, 2021 Volume 397 Number 10268 p1-70, e1
https://www.thelancet.com/journals/lancet/issue/current

Health Policy
Fragmented health systems in COVID-19: rectifying the misalignment between global health security and universal health coverage
Arush Lal, et al

The Lancet
Jan 02, 2021 Volume 397 Number 10268 p1-70, e1
https://www.thelancet.com/journals/lancet/issue/current

Viewpoint
The UK Government’s Vaccine Taskforce: strategy for protecting the UK and the world
Kate Bingham